# EDGAR Filing Document

**Accession Number:** 0001678660
**File Stem:** 0001193125-26-265835
**Filing Date:** 2026-6
**Character Count:** 6358
**Document Hash:** d38b7dfa788037dd6d0766961e964f3a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-265835.hdr.sgml**: 20260610

**ACCESSION NUMBER**: 0001193125-26-265835

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 9

**CONFORMED PERIOD OF REPORT**: 20260609

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20260610

**DATE AS OF CHANGE**: 20260610

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Prelude Therapeutics Inc
- **CENTRAL INDEX KEY:** 0001678660
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 811384762
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39527
- **FILM NUMBER:** 261079773

**BUSINESS ADDRESS:**
- **STREET 1:** 175 INNOVATION BOULEVARD
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19805
- **BUSINESS PHONE:** (302) 467-1280

**MAIL ADDRESS:**
- **STREET 1:** 175 INNOVATION BOULEVARD
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19805

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Prelude Therapeutics Inc.
- **DATE OF NAME CHANGE:** 20160630

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

------

**FORM** 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** June 9, 2026

------

Prelude Therapeutics Incorporated

**(Exact Name of Registrant as Specified in its Charter)**

------

---

| | | | |
|:---|:---|:---|:---|
| Delaware | 001-39527 | 001-39527 | 81-1384762 |
| **(State or other jurisdiction of<br>incorporation or organization)** | **(Commission<br>File Number)** | **(Commission<br>File Number)** | **(I.R.S. Employer<br>Identification No.)** |
| 175 Innovation Boulevard<br>Wilmington**,** Delaware | 175 Innovation Boulevard<br>Wilmington**,** Delaware | 19805 | 19805 |
| **(Address of principal executive offices)** | **(Address of principal executive offices)** | **(Zip Code)** | **(Zip Code)** |

---

**Registrant's telephone number, including area code:** (302) 467-1280

**Not Applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.0001 par value per share | PRLD | Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On June 9, 2026, Prelude Therapeutics Incorporated (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting") and the following proposals were approved by the Company's stockholders:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.Election of three Class III Directors, Krishna Vaddi, Paul Scherer, and Katina Dorton, each to serve a three-year term, which will expire at the 2029 Annual Meeting of Stockholders and until such time as their respective successors have been duly elected and qualified or until such director's earlier resignation or removal, based on the following votes:

---

| | | | |
|:---|:---|:---|:---|
| **Nominees** | **Shares For** | **Shares Withheld** | **Broker Non-Votes** |
| Krishna Vaddi, Ph.D. | 26,996,820 | 55,937 | 4,799,016 |
| Paul Scherer, MD, Ph.D. | 25,532,267 | 1,520,490 | 4,799,016 |
| Katina Dorton, J.D., MBA | 26,998,601 | 54,156 | 4,799,016 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Ratification of appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026, based on the following votes:

---

| | | | |
|:---|:---|:---|:---|
| **Shares For** | **Shares Against** | **Shares Abstaining** | **Broker Non-Votes** |
| 31,841,080 | 4,951 | 5,742 | 0 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Advisory vote to approve the 2025 compensation for the Company's named executive officers, based on the following votes:

---

| | | | |
|:---|:---|:---|:---|
| **Shares For** | **Shares Against** | **Shares Abstaining** | **Broker Non-Votes** |
| 26,869,142 | 107,500 | 76,115 | 4,799,016 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.Advisory vote on the frequency of advisory votes on the compensation for the Company's named executive officers, based on the following votes:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **1 Year** | **2 Years** | **3 Years** | **Abstain** | **Broker Non-Votes** |
| 26,877,941 | 65,638 | 103,237 | 5,941 | 4,799,016 |

---

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **PRELUDE THERAPEUTICS INCORPORATED** | **PRELUDE THERAPEUTICS INCORPORATED** |
| Date: June 10, 2026 | By: | /*s/ Bryant Lim* |
|  |  | Bryant Lim |
|  |  | Chief Legal Officer, Corporate Secretary, and Chief Financial Officer |

---

------